Elite in Progressive Multifocal Leukoencephalopathy

Patrick Vermersch

Lille, FR 
Clinical Trials:Currently Recruiting for 2 Trials
Elite in Progressive Multifocal Leukoencephalopathy
Lille, FR 
OverviewLocationsClinical Research

Overview

Patrick Vermersch practices in Lille, France. Mr. Vermersch is rated as an Elite expert by MediFind in the treatment of Progressive Multifocal Leukoencephalopathy. His top areas of expertise are Multiple Sclerosis (MS), Relapsing Multiple Sclerosis (RMS), CACH Syndrome, and Progressive Multifocal Leukoencephalopathy.

His clinical research consists of co-authoring 249 peer reviewed articles and participating in 14 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 9 articles in the study of Progressive Multifocal Leukoencephalopathy.

Gender
Male

Locations

Lille, 59000, France
Other Locations
Chilly, France
Nantes, France
Ivry-sur-seine, France

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

14 Clinical Trials

French Registry for Monitoring Pregnancies and Children of Women With Multiple Sclerosis Within The Observatoire Français de la Sclérose en Plaque (OFSEP) Cohort
French Registry for Monitoring Pregnancies and Children of Women With Multiple Sclerosis Within The Observatoire Français de la Sclérose en Plaque (OFSEP) Cohort
Enrollment Status: Recruiting
Publish Date: March 12, 2025
Intervention Type: Other
Serum Neurofilament-light Chain and Glial Fibrillary Acidic Proten (GFAP) Levels in Patients From the OFSEP Cohort at Different Landmarks of Multiple Sclerosis
Serum Neurofilament-light Chain and Glial Fibrillary Acidic Proten (GFAP) Levels in Patients From the OFSEP Cohort at Different Landmarks of Multiple Sclerosis
Enrollment Status: Recruiting
Publish Date: May 14, 2024
Intervention Type: Diagnostic test
A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing SAR442168 to Placebo in Participants With Primary Progressive Multiple Sclerosis (PERSEUS)
A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing SAR442168 to Placebo in Participants With Primary Progressive Multiple Sclerosis (PERSEUS)
Enrollment Status: Active_not_recruiting
Publish Date: August 17, 2025
Intervention Type: Drug
Study Drug: Tolebrutinib
Study Phase: Phase 3
A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing SAR442168 to Placebo in Participants With Nonrelapsing Secondary Progressive Multiple Sclerosis
A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing SAR442168 to Placebo in Participants With Nonrelapsing Secondary Progressive Multiple Sclerosis
Enrollment Status: Completed
Publish Date: July 02, 2025
Intervention Type: Drug
Study Drug: Tolebrutinib
Study Phase: Phase 3
LONG-TERM EFFECTIVENESS AND SAFETY EVALUATION OF OCRELIZUMAB IN FRENCH PATIENTS WITH PROGRESSIVE MS: CONSONANCE EXTENSION STUDY
LONG-TERM EFFECTIVENESS AND SAFETY EVALUATION OF OCRELIZUMAB IN FRENCH PATIENTS WITH PROGRESSIVE MS: CONSONANCE EXTENSION STUDY
Enrollment Status: Active_not_recruiting
Publish Date: May 17, 2024
Intervention Type: Drug
Study Phase: Phase 3
Effects of an Endurance Training Program at Ventilatory Threshold on the Walking Distance of Ambulatory Patients With Multiple Sclerosis
Effects of an Endurance Training Program at Ventilatory Threshold on the Walking Distance of Ambulatory Patients With Multiple Sclerosis
Enrollment Status: Terminated
Publish Date: March 26, 2024
Intervention Type: Other
Study Phase: Not Applicable
Multicentric, Randomized, Double-blind Versus Placebo Study Evaluating the Efficacy of Treatment With Cholecalciferol (Vitamin D3) for Delaying the Diagnosis of Multiple Sclerosis (MS) After a Clinically Isolated Syndrome (CIS). Comparison of Conversion Rates After 2 Years.
Multicentric, Randomized, Double-blind Versus Placebo Study Evaluating the Efficacy of Treatment With Cholecalciferol (Vitamin D3) for Delaying the Diagnosis of Multiple Sclerosis (MS) After a Clinically Isolated Syndrome (CIS). Comparison of Conversion Rates After 2 Years.
Enrollment Status: Completed
Publish Date: January 12, 2024
Intervention Type: Biological, Drug, Other
Study Drugs: Vitamin D, Lumbar Puncture, Blood Sampling, Urine Samples
Study Phase: Phase 3
Evaluating the Long-Term Outcomes and Durability of Effect Following Treatment With Cladribine Tablets for MS: An Exploratory Phase IV Ambispective Study of Patients Who Previously Participated in the CLARITY/CLARITY-EXT and ORACLE MS Clinical Trials (CLASSIC-MS)
Evaluating the Long-Term Outcomes and Durability of Effect Following Treatment With Cladribine Tablets for MS: An Exploratory Phase IV Ambispective Study of Patients Who Previously Participated in the CLARITY/CLARITY-EXT and ORACLE MS Clinical Trials (CLASSIC-MS)
Enrollment Status: Completed
Publish Date: October 31, 2023
Intervention Type: Other
Study Drug: Cladribine
Study Phase: Phase 4
A 2-Year Prospective Study to Assess Health-related Quality of Life In Subjects With Highly-Active Relapsing Multiple Sclerosis Treated With Mavenclad® (CLARIFY MS)
A 2-Year Prospective Study to Assess Health-related Quality of Life In Subjects With Highly-Active Relapsing Multiple Sclerosis Treated With Mavenclad® (CLARIFY MS)
Enrollment Status: Completed
Publish Date: September 14, 2023
Intervention Type: Drug
Study Drug: Mavenclad®
Study Phase: Phase 4
A National, Multi-center Study to Evaluate the Safety of Long Term Treatment With Teriflunomide 14 mg Once Daily in Patients With a First Clinical Episode Suggestive of Multiple Sclerosis in a Long-term Extension Period
A National, Multi-center Study to Evaluate the Safety of Long Term Treatment With Teriflunomide 14 mg Once Daily in Patients With a First Clinical Episode Suggestive of Multiple Sclerosis in a Long-term Extension Period
Enrollment Status: Completed
Publish Date: March 22, 2023
Intervention Type: Drug
Study Drug: Teriflunomide
Study Phase: Phase 3
Multi-center, Randomized, Double-blinded Study of Teriflunomide® in Radiologically Isolated Syndrome (RIS) The TERIS Study
Multi-center, Randomized, Double-blinded Study of Teriflunomide® in Radiologically Isolated Syndrome (RIS) The TERIS Study
Enrollment Status: Completed
Publish Date: March 17, 2023
Intervention Type: Drug
Study Drug: Teriflunomide [Aubagio]
Study Phase: Phase 3
Essai de Phase IV, Multicentrique, Ouvert, Visant à Tester la différence d'efficacité du Natalizumab, Versus le Fingolimod, 2 médicaments Ayant Une AMM Pour le Traitement de la sclérose en Plaques
Essai de Phase IV, Multicentrique, Ouvert, Visant à Tester la différence d'efficacité du Natalizumab, Versus le Fingolimod, 2 médicaments Ayant Une AMM Pour le Traitement de la sclérose en Plaques
Enrollment Status: Completed
Publish Date: August 25, 2020
Intervention Type: Procedure
Randomized Clinical Trial of Plasma Exchanges Versus Sham Plasma Exchanges in Disabling Multiple Sclerosis Acute Relapses Refractory to Steroid Treatment
Randomized Clinical Trial of Plasma Exchanges Versus Sham Plasma Exchanges in Disabling Multiple Sclerosis Acute Relapses Refractory to Steroid Treatment
Enrollment Status: Completed
Publish Date: January 16, 2018
Intervention Type: Procedure
Study Phase: Phase 3
Assessment of Neuropsychiatric Involvement in Systemic Sclerosis.
Assessment of Neuropsychiatric Involvement in Systemic Sclerosis.
Enrollment Status: Completed
Publish Date: November 09, 2017
Intervention Type: Other
Study Phase: Not Applicable
View 12 Less Clinical Trials

249 Total Publications

Discovery of Novel Benzamide-Based Sigma-1 Receptor Agonists with Enhanced Selectivity and Safety.
Discovery of Novel Benzamide-Based Sigma-1 Receptor Agonists with Enhanced Selectivity and Safety.
Journal: Molecules (Basel, Switzerland)
Published: July 09, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Vermersch's expertise for a condition
ConditionClose
View All 8 Advanced Conditions
View All 24 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile